Renalytix Ai Stock Total Asset
Renalytix AI fundamentals help investors to digest information that contributes to Renalytix's financial success or failures. It also enables traders to predict the movement of Renalytix Stock. The fundamental analysis module provides a way to measure Renalytix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Renalytix stock.
Renalytix |
Renalytix AI Company Total Asset Analysis
Renalytix's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Renalytix Total Asset | 7.97 M |
Most of Renalytix's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Renalytix AI is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Renalytix AI has a Total Asset of 7.97 M. This is 99.89% lower than that of the Health Care Technology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 99.97% higher than that of the company.
Renalytix Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Renalytix's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Renalytix could also be used in its relative valuation, which is a method of valuing Renalytix by comparing valuation metrics of similar companies.Renalytix is currently under evaluation in total asset category among its peers.
Renalytix Fundamentals
| Return On Equity | -10.73 | |||
| Return On Asset | -0.94 | |||
| Operating Margin | (9.43) % | |||
| Current Valuation | 36.84 M | |||
| Shares Outstanding | 82.96 M | |||
| Shares Owned By Insiders | 4.51 % | |||
| Shares Owned By Institutions | 4.13 % | |||
| Number Of Shares Shorted | 378.92 K | |||
| Price To Book | 18.77 X | |||
| Price To Sales | 9.85 X | |||
| Revenue | 2.29 M | |||
| Gross Profit | 720 K | |||
| EBITDA | (28.52 M) | |||
| Net Income | (33.46 M) | |||
| Cash And Equivalents | 32.36 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 8.54 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 2.48 X | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (30.11 M) | |||
| Short Ratio | 0.39 X | |||
| Earnings Per Share | (0.62) X | |||
| Target Price | 2.5 | |||
| Beta | 2.1 | |||
| Market Capitalization | 22.55 M | |||
| Total Asset | 7.97 M | |||
| Retained Earnings | (211.78 M) | |||
| Working Capital | 12.2 M | |||
| Net Asset | 7.97 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Renalytix Stock
If you are still planning to invest in Renalytix AI check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Renalytix's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |